Evaluate immunogenicity, reactogenicity and safety of 2 doses of GSK [GlaxoSmithKline] Biologicals' oral live attenuated HRV [human rotavirus] vaccine (RIX4414 at 10exp6.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh.

Trial Profile

Evaluate immunogenicity, reactogenicity and safety of 2 doses of GSK [GlaxoSmithKline] Biologicals' oral live attenuated HRV [human rotavirus] vaccine (RIX4414 at 10exp6.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs RIX 4414 (Primary) ; Poliovirus vaccine live oral
  • Indications Rotavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 25 Feb 2009 Results were published in Vaccine in Feb 2009.
    • 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
    • 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top